FDA Grants First Tumor-Agnostic Approval for RET Fusion-Positive Cancers
The FDA granted accelerated approval to selpercatinib (Retevmo) for adults with locally…
Browsing Tag
FusionPositive
Pralsetinib Shows Promise in Diverse RET Fusion-Positive Cancers
The highly selective RET inhibitor pralsetinib (Gavreto) achieved "rapid, robust, and durable"…